title: [Mediators of amyloidogenesis and cytokines in dialysis-related amyloidosis].
abstract: BACKGROUND
  Dialysis related amyloidosis (DRA) is a severe complication of the long-term dialysis treatment. beta 2 microglobulin and probably other factors influence the development of amyloid deposits. We investigated some of these factors during hemodialysis session.
  
  
  RESULTS
  We investigated 20 patients undergoing regular hemodialysis treatment. Patients were divided into AMYL group (with histologically proven DRA) and NE-AMYL group (without signs of DRA). Plasma levels of following factors were investigated using standard ELISA kits: serum amyloid A (SAA), interleukin-6 (IL-6), macrophage-colony stimulating factor (M-CSF). In addition plasma concentrations of C-reactive protein (CRP) and beta 2 microglobulin (beta 2M) were investigated in the AMYL group. All these parameters were studied during different time periods of the hemodialysis session. Plasma levels of SAA and IL-6 did not increase during hemodialysis session and we did not find any difference in plasma levels of these factors between the group of patients with AMYLand NE-AMYL. Plasma levels of M-CSF increased during hemodialysis and its levels in AMYL group were significantly higher in comparison with NE-AMYL group at the end of hemodialysis session (5345.10 +/- 340.42 vs. 3458.45 +/- 332.15 pg/ml, p = 0.0011). A linear correlation was found between plasma levels of SAA and CRP during hemodialysis whereas no correlation was found between plasma levels of beta 2M and other factors.
  
  
  CONCLUSIONS
  Our study suggests that plasma levels of M-CSF are increased in patients with chronic renal failure. Significant increase of M-CSF levels in the AMYL group could lead to greater activation of monocyte-macrophage system and could serve as factor supporting amyloid deposition process.
authors.affiliation: I. interní klinika 1. LF UK a VFN, Praha. rysavar@vfn.cz
authors.forename: R
authors.initials: R
authors.lastname: Rysavá
authors.forename: M
authors.initials: M
authors.lastname: Merta
authors.forename: V
authors.initials: V
authors.lastname: Tesar
authors.forename: J
authors.initials: J
authors.lastname: Lachmanová
authors.forename: S
authors.initials: S
authors.lastname: Sulková
authors.forename: J
authors.initials: J
authors.lastname: Bláha
mesh_terms: D000686:Amyloidosis / Q000097:blood / Q000209:etiology*; D002097:C-Reactive Protein / Q000032:analysis; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D000685:Serum Amyloid A Protein / Q000032:analysis*; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D016207:Cytokines; D015850:Interleukin-6; D000685:Serum Amyloid A Protein; D001613:beta 2-Microglobulin; D016173:Macrophage Colony-Stimulating Factor; D002097:C-Reactive Protein